Kymera Therapeutics, Inc. KYMR
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Sudan Loganathan | Stephens | 89.895 $ | 110 $ | 20.11 % | 11/12/2025 |
| Srikripa Devarakonda | Truist Financial | 86.27 $ | 116 $ | 29.73 % | 09/12/2025 |
| Andrew Fein | H.C. Wainwright | 86.87 $ | 134 $ | 47.13 % | 09/12/2025 |
| Derek Archila | Wells Fargo | 94.3 $ | 116 $ | 21.70 % | 09/12/2025 |
| Jeet Mukherjee | BTIG | 94.3 $ | 138 $ | 43.70 % | 08/12/2025 |
| Alex Thompson | Stifel Nicolaus | 93.7605 $ | 114 $ | 20.24 % | 08/12/2025 |
| Jeff Jones | Oppenheimer | 59.91 $ | 67 $ | 7.09 % | 04/11/2025 |
| Brad Canino | Guggenheim | 61.84 $ | 90 $ | 28.16 % | 03/11/2025 |
| Jeet Mukherjee | BTIG | 58.32 $ | 75 $ | 16.68 % | 22/10/2025 |
| Brian Abrahams | RBC Capital | 48.265 $ | 70 $ | 21.74 % | 16/09/2025 |
| Jeff Jones | Oppenheimer | 44.12 $ | 53 $ | 8.88 % | 27/06/2025 |
| Jeet Mukherjee | BTIG | 46.47 $ | 59 $ | 12.53 % | 26/06/2025 |
| Kelly Shi | Jefferies | 46.21 $ | 64 $ | 17.79 % | 25/06/2025 |
| Michael Schmidt | Guggenheim | 43.58 $ | 60 $ | 16.42 % | 03/06/2025 |
| Etzer Darout | BMO Capital | 44.08 $ | 55 $ | 10.92 % | 05/12/2024 |
| Derek Archila | Wells Fargo | 48.535 $ | 57 $ | 8.47 % | 02/12/2024 |
| Jeff Jones | Oppenheimer | 49.47 $ | 56 $ | 6.53 % | 27/09/2024 |
| Andy Chen | Wolfe Research | 47.78 $ | 65 $ | 17.22 % | 26/08/2024 |
| Andrew Fein | H.C. Wainwright | 40.31 $ | 60 $ | 19.69 % | 08/08/2024 |
| Andrew Fein | H.C. Wainwright | 32.29 $ | 46 $ | 13.71 % | 17/06/2024 |
| Edward Tenthoff | Piper Sandler | 34.835 $ | 56 $ | 21.17 % | 23/05/2024 |
| Jeff Jones | Oppenheimer | 36.3 $ | 52 $ | 15.70 % | 03/05/2024 |
| Michael Turits | Morgan Stanley | 29.11 $ | 45.2 $ | 16.09 % | 06/12/2022 |
| Richard Law | Credit Suisse | 29.11 $ | 32 $ | 2.89 % | 06/12/2022 |
| Eliana Merle | UBS | 43.2 $ | 80 $ | 36.80 % | 20/05/2021 |